FIELD: chemistry.
SUBSTANCE: in the general formula I 
R1 are selected from methyl, ethyl, propyl, cyclopropyl, cyclopropylmethyl, difluoroethyl and 2,2,2-trifluoroethyl; R2 is selected from hydrogen, C1-6alkyl, C1-6alkyloxy, C1-6alkylaminoC1-6alkyl, C3-6cycloalkyl, saturated 4-6-membered heterocycloalkyl containing 1-2 heteroatoms selected from nitrogen, oxygen or nitrogen and oxygen, phenyl and mono- or bicyclic C5-10heteroaryl containing in the ring 1 to 2 nitrogen atoms or a nitrogen atom and a sulphur atom, where R2 is substituted with 0, 1, 2 or 3 R3 substitutes; n is 1, 2, 3; A is selected from pyrrolidinyl, piperidinyl, azetidinyl, azaspiro[2.4]hept-7-yl and azepanyl; L is selected from NH and N(C1-10alkyl); K is selected from a chemical bond, C(O), CH2, -C(O)N(Rb)-(CH2)m- and C2-4alkynylene; Rb is H or C1-10alkyl, m is 0, 1, 2, or 3; R3 are independently selected from: halogen, C1-6alkyl, C2-6alkenyl, C1-6alkyl(oxy), C1-6alkyl(oxy)(carbonyl), C1-6alkyl(carbonyl), phenyl(oxy), phenyl(oxy)(carbonyl), phenylC1-4alkyl(oxy)(carbonyl), phenylC1-4alkyl(carbonyl), C3-12cycloalkyl(carbonyl), C3-12cycloalkylC1-4alkyl, C5-12bicycloalkyl(carbonyl), C7-8spirocycloalkyl(carbonyl), 5-10 membered mono- or bicyclic heteroaryl containing 1 to 3 heteroatoms in a ring selected from nitrogen or nitrogen and sulphur, 5-10 membered mono- or bicyclic heteroaryl(carbonyl), wherein the heteroaryl contains 1 to 3 ring heteroatoms selected from nitrogen or nitrogen and / or sulphur, (C3-7)heterocycloalkyl containing 1-2 heteroatoms selected from nitrogen and oxygen, (C3-7)heterocycloalkyl (carbonyl), wherein heterocycloalkyl contains 1-2 heteroatoms selected from nitrogen and oxygen, C1-6alkylamino(carbonyl), C3-6cycloalkylamino(carbonyl), -C(O)2(C1-10alkyl), -(C0-6alkyl)CO2H, oxo(=O); C1-10alkylS(O)2, amino, (C0-10alkyl)1-2amino, C1-4acylamino, hydroxyl, (C1-6alkyl)OH, cyano; where R3 each is substituted with 0, 1, 2 R4 substitutes, and each R4 are independently selected from halogen, C1-10alkyl, C1-10alkyl(oxy), phenyl, 5-6 membered heteroaryl containing an oxygen or nitrogen ring atom, (C4) of heterocycloalkyl containing a nitrogen, oxygen or sulphur atom, or S(O)2 group in the ring, (C4) heterocycloalkyl (carbonyl), wherein the heterocycloalkyl contains a nitrogen, oxygen or sulphur atom, or S(O)2 group in the ring, oxo(=O), amino, (C1-6alkyl)1-2amino, (C1-6alkyl)OH, C1-10alkoxy, cyano and C1-6haloalkyl. Invention also includes specific compounds as defined in claim 2.
EFFECT: invention relates to a novel compound of formula I or a pharmaceutically acceptable salt or stereoisomer thereof, which have the properties of a PI3K-alpha inhibitor and relative selectivity for PI3K delta-mediated disease or disease state selected from arthritis, asthma and obstructive diseases of the upper respiratory tract, autoimmune diseases or disorders and cancer.
23 cl, 16 tbl, 32 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | 2013 |
|
RU2658006C2 |
| MELANOCORTIN RECEPTOR AGONISTS | 2007 |
|
RU2411240C2 |
| INHIBITORS OF HEPATITIS C VIRUS HAVING RODLIKE CHAIN AND COMPRISING {2-[4-(BIPHENYL-4-YL)-1H-IMIDAZO-2-YL]PYRROLIDIN-1-CARBONYLMETHYL}AMINE FRAGMENT | 2012 |
|
RU2625787C2 |
| GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | 2014 |
|
RU2664533C2 |
| MORPHOLINOPURINE DERIVATIVES, HAVING PI3K AND/OR mTOR INHIBITING ACTIVITY | 2009 |
|
RU2490269C2 |
| ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 2020 |
|
RU2824528C2 |
| MEDICINAL COMPOUNDS | 2014 |
|
RU2691105C1 |
| BI-ARYL-META-PYRIMIDINE KINASE INHIBITORS | 2006 |
|
RU2597364C2 |
| BI-ARYL-META-PYRIMIDINE KINASE INHIBITORS | 2006 |
|
RU2589878C2 |
| INHIBITORS OF AKT ACTIVITY | 2010 |
|
RU2579513C2 |
